Virtual Tumor Board Challenge: Navigating Treatment Selection and Sequencing in Metastatic Prostate Cancer

Subject areas

This course counts toward the state boards and subject areas below.

Disclosure statements

DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES

i3 Health endorses the standards of the ACCME and ANCC that require everyone in a position to control the content of a CME/NCPD activity to disclose all financial relationships with ineligible companies that are related to the content of the CME/NCPD activity. CME/NCPD activities must be balanced, independent of commercial bias, and promote improvements or quality in healthcare. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.

A conflict of interest is created when an individual has an opportunity to affect CME/NCPD content about products or services of an ineligible company with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.

i3 Health will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.

Relevant financial relationships exist between the following individuals and ineligible companies:

The i3 Health planners, reviewers, and managers have nothing to disclose.

Stephen Freedland, MD, discloses that he has served on an advisory board or panel for Astellas, AstraZeneca, Bayer, Janssen, Merck, Novartis, Pfizer, Sanofi, Sumitomo, and Tolmar; that he has served on a speaker’s bureau for Astellas and Pfizer; and that he has served as a consultant for Astellas, AstraZeneca, Bayer, Janssen, Merck, Novartis, Pfizer, Sanofi, Sumitomo, and Tolmar.

Andrés Matoso, MD, discloses that he has served on an advisory board or panel for Lilly and that he has served as a consultant for Compugen and Diagnexia.

Jennifer Sutton, RN, BS, CCRC, discloses that she has served on an advisory board or panel for Bayer and Merck; that she has served on a speaker’s bureau for Bayer; and that she has served as a consultant for Janssen.

i3 Health has mitigated all relevant financial relationships.